Ticker Details
Novavax, Inc. Novavax Inc is a clinical-stage vaccine company. It is engaged in the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants.
IPO Date:	December 13, 1995
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$1.47B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.98 | 4.12%
Avg Daily Range (30 D):	$0.21 | 2.53%
Avg Daily Range (90 D):	$0.26 | 2.86%

Institutional Daily Volume
Avg Daily Volume:	4.06M
Avg Daily Volume (30 D):	3.24M
Avg Daily Volume (90 D):	3.93M

Trade Size
Avg Trade Size (Sh.):	195
Avg Trade Size (Sh.) (30 D):	120
Avg Trade Size (Sh.) (90 D):	126

Institutional Trades
Total Institutional Trades:	9,145
Avg Institutional Trade:	$3.47M
Avg Institutional Trade (30 D):	$2.23M
Avg Institutional Trade (90 D):	$2.43M
Avg Institutional Trade Volume:	.1M
Avg Institutional Trades (Per Day):	3

Market Closing Trades
Avg Closing Trade:	$6.37M
Avg Closing Trade (30 D):	$3.07M
Avg Closing Trade (90 D):	$3.64M
Avg Closing Volume:	239.74K

News

May 13, 2026 @ 5:15 PM 3 Reasons Not to Buy Into the Hantavirus-Related B... Source: Prosper Junior Bakiny

May 8, 2026 @ 6:18 PM What's Going On With Novavax Stock On Friday? Source: Vandana Singh

Jan 29, 2026 @ 1:30 PM This Beaten-Down Biotech Is Showing Signs of Life.... Source: Prosper Junior Bakiny

Jan 26, 2026 @ 10:02 PM Stock Market Today, Jan. 20: ImmunityBio Soars Aga... Source: Josh Kohn-Lindquist

Sep 26, 2025 @ 4:08 AM Robert F. Kennedy Jr. Faces Impeachment Push From ... Source: Vishaal Sanjay

Financials
	TTM	Q2 2026	Q1 2026
Basic EPS	$-1.52	$-.32	$-.06
Diluted EPS	$-1.58	$-.32	$-.06
Revenue	$413.8M	$56.7M	$139.51M
Gross Profit	$325.26M	$42.45M	$108.82M
Net Income / Loss	$-247.73M	$-53.39M	$-9.49M
Operating Income / Loss	$-234.12M	$-54.91M	$-15.43M
Cost of Revenue	$88.54M	$14.25M	$30.7M
Net Cash Flow	$-72.94M	$-36.89M	$-23.13M
PE Ratio

Splits
May 10, 2019	1:20